Comments
US stocks edged lower on Monday on the heels of strong gains in the prior week, as investors weighed fluctuations in the dollar and its impact on other markets, including crude prices.
Equity markets fluctuated between modest gains and slight losses, tracking the movement of energy stocks as crude oil prices were caught between weakness in the US dollar and concerns about oversupply. The S&P 500 energy sector was up 0.2 per cent after earlier gaining as much as 0.9 per cent.
The action in the dollar has closely affected stocks of late as traders anticipate monetary policy tightening by the Federal Reserve sometime later this year. The 20-day correlation between the dollar index and the S&P 500 sits at -0.79. The dollar index was down 0.9 per cent on the day.
“People are now way too focused on earnings, which start in a week or two, and what the impact of the stronger dollar will be and until that happens it is going to hold the market in check,’’ said Ken Polcari, director of the NYSE floor division at O'Neil Securities in New York.
While the dollar’s rise has been beneficial for consumers, its rapid strengthening has been a problem for a large portion of the market, such as commodities firms and exporters.
"People are prepared for the strength of the dollar to hurt earnings, but by how much they don't know yet," said Polcari.
The Dow Jones industrial average fell 11.61 points or 0.06 per cent to 18,116.04, the S&P 500 lost 3.68 points, or 0.17 per cent to 2,104.42 and the Nasdaq Composite dropped 15.44 points or 0.31 per cent to 5,010.97.
The Nasdaq snapped a five-session winning streak but remains less than 1 per cent from a closing record set on March 10, 2000.
In a choppy session, Brent settled up 1.1 per cent at $55.92 a barrel, while US crude settled up 1.9 per cent at $47.45. The decline in the dollar outweighed oversupply concerns after top exporter Saudi Arabia said it would only mull cutting output if producers outside OPEC do so as well.
Kansas City Southern shares dropped 8 per cent to $106.48 as the worst performer on the S&P 500 after the railroad cut its full year revenue forecast.
The Nasdaq Biotech index fell for the first time in nine sessions, down 2.2 per cent, after running up nearly 20 percent from its February low.
Volume was light, with about 5.42 billion shares traded on US exchanges, below the 6.86 billion average so far this month, according to BATS Global Markets.
Advancing issues outnumbered declining ones on the NYSE by 1,764 to 1,266, for a 1.39-to-1 ratio; on the Nasdaq, 1,472 issues rose and 1,287 fell for a 1.14-to-1 ratio favouring advancers.
The S&P 500 posted 62 new 52-week highs and 1 new low; the Nasdaq Composite recorded 153 new highs and 34 new lows.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.